Literature DB >> 18412245

Cancer and mortality among users and nonusers of snus.

Ann Roosaar1, Anna L V Johansson, Gunilla Sandborgh-Englund, Tony Axéll, Olof Nyrén.   

Abstract

Scandinavian moist snuff (snus) is claimed to be a safer alternative to smoking. We aimed to quantify cancer incidence among male snus users and to shed light on the net health outcome by studying their overall mortality. A cohort, comprised of 9,976 men who participated in a population-based survey, was compiled in 1973-74. Follow-up until January 31, 2002, was accomplished through record-linkages with nation-wide and essentially complete registers of demographics, cancer and causes of deaths. Adjusted relative risks among exposed relative to unexposed men were estimated using Cox proportional hazards regression. The cohort members contributed more than 220,000 person-years at risk for cancer. A statistically significant increase in the incidence of the combined category of oral and pharyngeal cancer among daily users of snus (incidence rate ratio 3.1, 95% confidence interval 1.5-6.6) was found. Overall mortality was also slightly increased (hazard ratio 1.10, 95% confidence interval 1.01-1.21). Although the combined previous literature on snus and oral cancer weigh toward no association, this population-based prospective study provided suggestive evidence of snus-related risks that cannot be lightly ignored. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18412245     DOI: 10.1002/ijc.23469

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  LC-MS/MS Analysis of Sugars, Alditols, and Humectants in Smokeless Tobacco Products.

Authors:  Liqun Wang; Stephen Stanfill; Liza Valentin-Blasini; Clifford H Watson; Roberto Bravo Cardenas
Journal:  Beitr Tab Int       Date:  2019-06-13

Review 2.  Systematic review of the relation between smokeless tobacco and cancer in Europe and North America.

Authors:  Peter N Lee; Jan Hamling
Journal:  BMC Med       Date:  2009-07-29       Impact factor: 8.775

Review 3.  Non-cigarette tobacco and the lung.

Authors:  Michael Schivo; Mark V Avdalovic; Susan Murin
Journal:  Clin Rev Allergy Immunol       Date:  2014-02       Impact factor: 8.667

4.  Snus use, smoking and survival among prostate cancer patients.

Authors:  Kathryn M Wilson; Sarah C Markt; Fang Fang; Caroline Nordenvall; Jennifer R Rider; Weimin Ye; Hans-Olov Adami; Pär Stattin; Olof Nyrén; Lorelei A Mucci
Journal:  Int J Cancer       Date:  2016-12-15       Impact factor: 7.396

5.  Prevalence of trial of snus products among adult smokers.

Authors:  Lois Biener; Kristen McCausland; Laurel Curry; Jennifer Cullen
Journal:  Am J Public Health       Date:  2011-02-17       Impact factor: 9.308

6.  Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study.

Authors:  Michael Kotlyar; Louise A Hertsgaard; Bruce R Lindgren; Joni A Jensen; Steven G Carmella; Irina Stepanov; Sharon E Murphy; Stephen S Hecht; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-11-10       Impact factor: 4.254

7.  Perceived Health Risks of Snus and Medicinal Nicotine Products.

Authors:  Dorothy K Hatsukami; R I Vogel; Herb H Severson; Joni A Jensen; Richard J O'Connor
Journal:  Nicotine Tob Res       Date:  2015-09-18       Impact factor: 4.244

Review 8.  What works to prevent adolescent smoking? A systematic review of the National Cancer Institute's Research-Tested Intervention Programs.

Authors:  Elyse J Sherman; Brian A Primack
Journal:  J Sch Health       Date:  2009-09       Impact factor: 2.118

9.  Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study.

Authors:  Robert P Murray; John E Connett; Lisa M Zapawa
Journal:  Nicotine Tob Res       Date:  2009-07-01       Impact factor: 4.244

Review 10.  Tobacco harm reduction: Past history, current controversies and a proposed approach for the future.

Authors:  Dorothy K Hatsukami; Dana M Carroll
Journal:  Prev Med       Date:  2020-04-23       Impact factor: 4.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.